




Kristen N Ganjoo

Professor of Medicine (Oncology)

Medicine - Oncology

 Curriculum Vitae available Online

 Resume available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

900 Blake Wilbur Dr

3rd Fl

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-3321

Bio

CLINICAL FOCUS

- Cancer > Sarcoma
- Soft Tissue Sarcoma
- Gastrointestinal Stromal Tumors
- Ewing's Sarcoma
- Osteosarcoma
- Medical Oncology
- Uterine leiomyosarcoma
- Leiomyosarcoma
- Liposarcoma
- Synovial sarcoma

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Assistant Professor of Medicine, Indiana University, (2000-2004)
- Assistant Professor of Medicine, Stanford University, (2004-2015)
- Associate Professor of Medicine, Stanford University, (2015-2023)
- Professor of Medicine, Stanford University, (2023- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Associate Member, American Society of Clinical Oncology (1998 - present)

- Investigator, Sarcoma Alliance for Research through Collaboration (SARC) (2008 - present)
- Physician Leader, Stanford Cancer Center- Sarcoma (2008 - present)
- Board Member, National Comprehensive Cancer Network Task Force (NCCN)-Soft Tissue Sarcoma (2009 - present)
- Clinical Research Group Leader-Sarcoma, Stanford University (2010 - present)
- Member, Connective Tissue Oncology Society (CTOS) (2010 - present)
- Member, Institutional Review Board- Stanford (2012 - present)
- Member, Scientific Review Board- Stanford Cancer Institute (2013 - present)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2023)
- Fellowship: Indiana University School Of Medicine (2000) IN
- Residency: Indiana University (1997) IN
- Internship: Indiana University (1995) IN
- Medical Education: University of South Alabama Medical Center (1994) AL
- BS, UC Davis , Biological Sciences (1989)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical research with new and novel therapies for sarcomas including anti-angiogenesis agents and targeted agents. .

CLINICAL TRIALS

- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- Phase 1 Study of Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal , Recruiting
- Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor, Recruiting
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo), Recruiting
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies, Not Recruiting
- Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms, Not Recruiting
- Drug Interaction Study to Assess the Effect of Pexidartinib on Pharmacokinetics of CYP3A4 and CYP2C9, Not Recruiting
- Expanded Access ABI-009 in Advanced PEComa & Malignancy w/ GeneticMutations /mTOR Pathway Activation, Not Recruiting
- Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated w/ RCHOP +/- XRT, Not Recruiting
- Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma, Not Recruiting
- Phase 1b/2 AMG 655 + Doxorubicin as 1st Line for Locally Advanced or Metastatic Soft Tissue Sarcoma, Not Recruiting
- Phase I MGD009 in Unresectable /Metastatic B7-H3-Expressing Neoplasms, Not Recruiting
- Phase I Trametinib in Unresectable or Metastatic Epithelioid Hemangioendothelioma, Not Recruiting
- Phase I/II DCC-3014 in Advanced Tumors and Tenosynovial Giant Cell Tumor, Not Recruiting
- Phase I/II FPA008 in Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor, Not Recruiting
- Phase I/II TH-302 in Combination with Doxorubicin for Advanced Soft Tissue Sarcoma, Not Recruiting

- Phase II 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma, Not Recruiting
- Phase II ABI-009 in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa), Not Recruiting
- Phase II ADP-A2M4 SPEAR T Cells in Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma, Not Recruiting
- Phase II Cabozantinib (Dual Inhibitor of MET & VEGFR) in Metastatic Refractory Soft Tissue Sarcoma, Not Recruiting
- Phase II Cabozantinib Combined w/ PD-1 & CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma, Not Recruiting
- Phase II Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma, Not Recruiting
- Phase II Denosumab in Giant Cell Tumor of Bone, Not Recruiting
- Phase II Envafolelimab +/- Ipilimumab in Advanced or Metastatic UP Sarcoma or Myxofibrosarcoma, Not Recruiting
- Phase II Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma, Not Recruiting
- Phase II Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors, Not Recruiting
- Phase II Nab-Sirolimus in SolidTumors Harboring PathogenicInactivatingAlterations in TSC1/TSC2 Genes, Not Recruiting
- Phase II Nilotinib in Relapsed/Metastatic PVNS or Diverse-Type Giant Cell Tumor, Not Recruiting
- Phase II NY-ESO-1-Specific(c259) T Cells +/- OtherAgents in HLA-A2+ w/ NY-ESO-1 &/or LAGE-1a + ST , Not Recruiting
- Phase II of CMB305 & Atezolizumab in Locally Advanced / Relapsed or Metastatic NY-ESO-1 Sarcoma , Not Recruiting
- Phase II Pazopanib in Imatinib & Sunitinib Intolerant Gastrointestinal Stromal Tumors, Not Recruiting
- Phase II R1507 for Recurrent or Refractory Ewing's, Osteo-, Synovial, Rhabdomyo- and Other Sarcomas, Not Recruiting
- Phase II Regorafenib in Refractory Liposarcoma, Osteogenic Sarcoma, & Ewing/Ewing-Like Sarcomas, Not Recruiting
- Phase II/III Selinexor (KPT-330) vs Placebo in Advanced Unresectable Dedifferentiated Liposarcoma, Not Recruiting
- Phase II/III Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma, Not Recruiting
- Phase IIb INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Soft Tissue Sarcoma, Not Recruiting
- Phase IIb/III Trabectedin 3-hour or 24-hour Infusion + Doxorubicin in Advanced or Metastatic Sarcoma, Not Recruiting
- Phase III (Atezolizumab vs Placebo) + Cobimetinib & Vemurafenib in Metastatic Melanoma, Not Recruiting
- Phase III Aldoxorubicin vs Investigator's Choice in Soft Tissue Sarcomas, Not Recruiting
- Phase III DCC-2618 In AdvanCed Gastrointestinal Stromal TUMorS w/ Tx w/ Prior Anticancer Therapies, Not Recruiting
- Phase III DCC-2618 vs Sunitinib in Advanced Gastrointestinal Stromal Tumors after Tx w/ Imatinib, Not Recruiting
- Phase III Doxorubicin +Olaratumab vs Doxorubicin +Placebo in Advanced/Metastatic Soft Tissue Sarcoma, Not Recruiting
- Phase III Eribulin vs Dacarbazine in Soft Tissue Sarcoma, Not Recruiting
- Phase III Oral PLX3397 in Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath, Not Recruiting
- Phase III Randomized Trial of TRC105 and Pazopanib Versus Pazopanib in Advanced Angiosarcoma, Not Recruiting
- Phase III TH-302 + Doxorubicin VS Doxorubicin in Locally Advanced Unresectable / Metastatic Sarcoma, Not Recruiting
- Phase IIIa YONDELIS (Trabectedin) or Dacarbazine for Tx of Liposarcoma or Leiomyosarcoma, Not Recruiting
- PhaseII CytoreductiveSurgery&HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in UterineLeiomyosarcoma, Not Recruiting
- Prospective Eval of Outcomes of Radiosurgical Treatment of NSCLC, Not Recruiting
- Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab, Not Recruiting
- Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma, Not Recruiting
- Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma, Not Recruiting
- Trial of Dasatinib in Advanced Sarcomas, Not Recruiting
- Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies, Not Specified
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma, Not Specified

- Ph 2 Open-label, Two-stage of CC-4047 for Relapsed or Refractory Systemic Anticancer Therapy, Not Specified
- Phase I Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patient w/ Synovial Sarcoma, Not Specified

Publications

PUBLICATIONS

- **Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma.** *Cancers*
Zhou, M., Bui, N., Rathore, R., Sudhaman, S., George, G. V., Malashevich, A. K., Malhotra, M., Liu, M. C., Aleshin, A., Ganjoo, K. N.
2022; 15 (1)
- **Management of Patients with Newly Diagnosed Desmoid Tumors in a First-Line Setting.** *Cancers*
Testa, S., Bui, N. Q., Charville, G. W., Avedian, R. S., Steffner, R., Ghanouni, P., Mohler, D. G., Ganjoo, K. N.
2022; 14 (16)
- **Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma** *CANCERS*
Pan, M., Trieu, M. K., Sidhu, M., Yu, J., Seto, T., Ganjoo, K.
2021; 13 (8)
- **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review** *IMMUNOTHERAPY*
Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H., Ganjoo, K.
2020; 12 (18): 1303–12
- **NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*
von Mehren, M., Kane, J. M., Bui, M. M., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Homsy, J., Keedy, V., Kelly, et al
2020; 18 (12): 1604–12
- **Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas** *JCO PRECISION ONCOLOGY*
Przybyl, J., Spans, L., Lum, D. A., Zhu, S., Vennam, S., Forgo, E., Varma, S., Ganjoo, K., Hastie, T., Bowen, R., Debiec-Rychter, M., van de Rijn, M.
2019; 3
- **Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma** *CLINICAL CANCER RESEARCH*
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A. A., Diehn, M., van de Rijn, et al
2018; 24 (11): 2688–99
- **Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma** *JOURNAL OF CLINICAL ONCOLOGY*
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., Ganjoo, K. N.
2014; 32 (29): 3299-?
- **A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study** *CANCER*
Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. C., Chugh, R., Ladanyi, M., Grippo, J. F., Dall, G., Staddon, A. P., Chawla, S. P., Maki, R. G., Araujo, et al
2014; 120 (16): 2448-2456
- **Gastrointestinal stromal tumors, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al
2014; 12 (6): 853-862
- **Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al

2014; 12 (4): 473-483

- **A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.** *Annals of oncology*
Ganjoo, K. N., Villalobos, V. M., Kamaya, A., Fisher, G. A., Butrynski, J. E., Morgan, J. A., Wagner, A. J., D'adamo, D., McMillan, A., Demetri, G. D., George, S.
2014; 25 (1): 236-240
- **R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study** *JOURNAL OF CLINICAL ONCOLOGY*
Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., Ganjoo, K. N., Schuetze, S. M., Juergens, et al
2011; 29 (34): 4541-4547
- **Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour** *DRUGS*
Ganjoo, K. N., Patel, S.
2011; 71 (3): 321-330
- **A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma** *ONCOLOGY*
Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D., Adkins, D., Okuno, S. H., Lorente, G., Kroll, S., Langmuir, V. K., Chawla, S. P.
2011; 80 (1-2): 50-56
- **New Developments in Targeted Therapy for Soft Tissue Sarcoma** *CURRENT ONCOLOGY REPORTS*
Ganjoo, K. N.
2010; 12 (4): 261-265
- **Soft Tissue Sarcoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Demetri, G. D., Antonia, S., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., Heslin, M. J., Hutchinson, R. J., Kane, J. M., Letson, G. D., McGarry, et al
2010; 8 (6): 630-674
- **NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W., Raut, C. P., Riedel, R. F., Schuetze, S., Sundar, H. M., Trent, J. C., Wayne, et al
2010; 8: S1-S43
- **Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas** *CANCER*
Ganjoo, K., Jacobs, C.
2010; 116 (5): 1177-1183
- **Trabectedin: an anticancer drug from the sea** *EXPERT OPINION ON PHARMACOTHERAPY*
Ganjoo, K. N., Patel, S. R.
2009; 10 (16): 2735-2743
- **Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec** *LEUKEMIA & LYMPHOMA*
Ganjoo, K. N., Demetri, G. D., Jacobs, C., Patel, S.
2009; 50 (11): 1882-1884
- **A plain language summary of the AMPECT study: *nab*-sirolimus for advanced malignant perivascular epithelioid cell tumors** *FUTURE ONCOLOGY*
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., Polson, K. M., Yalamanchili, S., Deboer, et al
2025: 1-13
- **Soft Tissue Sarcoma, Version 1.2025 *Featured Updates to the NCCN Guidelines*** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Kane III, J. M., Armstrong, S. A., Balach, T., Bishop, A. J., Buehler, D., Carr-Ascher, J., Choy, E., Cipriano, C., Connolly, M., Dann, A., Davis, E. J., Dry, et al
2025; 23 (12)

- **SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.** *Genome medicine*
Testa, S., Pal, A., Subramanian, A., Varma, S., Tang, J. P., Graham, D., Arfan, S., Pan, M., Bui, N. Q., Ganjoo, K. N., Dry, S., Huang, P., van de Rijn, et al
2025; 17 (1): 89
- **A multi-center retrospective outcomes analysis of patients with localized synovial sarcoma.**
Testa, S., Zhou, M., Schulte, B., Wang, V., Kenny, K., Peng, A., Desai, A. M., Bockorny, B., Baghian, A., Schmidt, D. R., Okimoto, R., Bui, N., Pan, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: e23555
- **Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma.**
Zhou, M., Pan, M., Bui, N., Ganjoo, K. N.
LIPPINCOTT WILLIAMS & WILKINS.2025: 11531
- **Musculoskeletal Tumor Care Disparities Prior to Initiation of Treatment Among Newly Diagnosed Adult Patients.** *Cancers*
Li, L. J., Bui, N., Moding, E. J., Steffner, R., Mohler, D., Ganjoo, K., Pan, M.
2025; 17 (9)
- **Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center.** *Diseases (Basel, Switzerland)*
Kim, T., Hao, C., Pan, M., Ganjoo, K. N., Bui, N. Q.
2025; 13 (3)
- **Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Lee, A. Q., Hao, C., Pan, M., Ganjoo, K. N., Bui, N. Q.
2024
- **Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers.** *Journal of hematology & oncology*
Pan, M., Zhou, M., Xie, L., Bui, N., Ganjoo, K.
2024; 17 (1): 124
- **Genomic, epigenomic and transcriptomic inter- and intra-tumor heterogeneity in desmoid tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
De Bellis, C., Vennam, S., Eeles, C., Rahimizadeh, P., Cates, J., Stricker, T., Hoffman, J., Ganjoo, K., Charville, G. W., Haibe-Kains, B., van de Rijn, M., Przybyl, J.
2024
- **Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study.** *Cancers*
Zhang, E., Farag, S., Dietz, H., Wang, D., Hirbe, A., Ganjoo, K., Van Tine, B., Zaid, S., Miah, A., Keedy, V., Davis, E., Bui, N.
2024; 16 (22)
- **Response to treatment with nab-Sirolimus in patients with perivascular epithelioid cell sarcoma of gynecologic or peritoneal origin: Subgroup analysis from AMPECT**
Herzog, T., Dockery, L., Dickson, M., Ganjoo, K., Ravi, V., Ding, L., Schmid, A., Palma, N., Navarro, W., Wagner, A.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2024: S39-S40
- **Monitoring Response Using Circulating Tumor DNA in Undifferentiated Pleomorphic Sarcoma: A Case Report.** *Cureus*
Siy, A. B., Zhou, M., Boncompagni, A. C., Charville, G., Poultides, G., Ganjoo, K. N.
2024; 16 (11): e74837
- **Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior anticolonystimulating factor 1 (CSF1) therapy: Ongoing phase II study**
D'Amato, G., Wagner, A. J., Ganjoo, K. N., Stacchiotti, S., Gelderblom, H., Ryan, C. W., Palmerini, E., Ravi, V., Saleh, R., Le Cesne, A., Bernthal, N. M., van de Sande, M., Narasimhan, et al
ELSEVIER.2024: S1054
- **Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy**
Lee, A., Hao, C., Pan, M., Ganjoo, K. N., Bui, N.
LIPPINCOTT WILLIAMS & WILKINS.2024

- **Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study**
Alshibany, A., Zhou, M., Warren, E., Ganjoo, K. N., Demicco, E., Feeney, J., Lee, J., Shultz, D., Spickard, E., Bui, N., Cardona, K., Salawu, A., Razak, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Prognostic factors for patients with sarcoma with brain metastases**
Zhang, E., Farag, S., Dietz, H., Wang, D., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Miah, A. B., Zaidi, S. H., Keedy, V., Davis, E. J., Bui, N.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.** *Lancet (London, England)*
D'Angelo, S. P., Araujo, D. M., Abdul Razak, A. R., Agulnik, M., Attia, S., Blay, J. Y., Carrasco Garcia, I., Charlson, J. A., Choy, E., Demetri, G. D., Druta, M., Forcade, E., Ganjoo, et al
2024
- **A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Schuetze, S. M., Ballman, K. V., Heise, R., Ganjoo, K. N., Davis, E. J., George, S., Burgess, M. A., Choy, E., Shepard, D. R., Tinoco, G., Hirbe, A., Kelly, C. M., Attia, et al
2024
- **Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET.** *Seminars in nuclear medicine*
Guja, K. E., Ganjoo, K. N., Iagaru, A.
2024
- **Single cell pharmacogenomic pipeline identifies novel opportunities in uterine leiomyosarcoma**
Daniel, S. K., Foster, D., Nosrati, F., Korah, M., Fallah, M., Sun, B. J., Loftus, T., Hu, D., Dua, M., Visser, B., Poultsides, G., Kirane, A., Longaker, et al
SPRINGER.2024: S42
- **Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., Ding, L., Schmid, A. N., Navarro, et al
2024: JCO2302266
- **Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy.** *Nature cancer*
Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, et al
2024
- **PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma.** *BJC reports*
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N., Bien, J., Siy, A., Achacoso, N., Solorzano, A. V., Tse, P., Chung, E., Hu, W., Thomas, et al
2024; 2 (1): 9
- **A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages.** *Acta neuropathologica communications*
Rogawski, D., Wheeler, J., Nie, E., Zhu, W., Villanueva, E., Coffey, G., Ma, Q., Ganjoo, K., Fischbein, N., Iv, M., Vogel, H., Nagpal, S.
2024; 12 (1): 15
- **Surgery and stereotactic radiosurgery for spinal leiomyosarcoma: a single-institution retrospective series and systematic review.** *Journal of neurosurgery. Spine*
Zamarud, A., Marianayagam, N. J., Sekar, V., Testa, S., Park, D. J., Yener, U., McCleary, T. L., Yoo, K. H., Emrich, S., Tayag, A., Ustrzynski, L., Pollom, E., Soltys, et al
2023: 1-13
- **Response to Immunotherapy in Sclerosing Epithelioid Fibrosarcoma: Case Report and Literature Review.** *Cureus*
Koerner, A. S., Zhou, M., Brook, A., Yoon, S. S., Ganjoo, K. N.
2023; 15 (12): e50967

- **Sex-Dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N. Q., Bien, J., Siy, A., Achacoso, N., Solorzano, A. V., Tse, P., Chung, E., Thomas, S., Habel, et al
2023
- **Epstein Barr Virus-Positive Lymphoproliferative Disorder Following Lymphodepletion for MAGE A4 Adoptive Cellular Therapy in a Patient with Synovial Sarcoma: A Case Report.** *Case reports in oncology*
Zhou, M., Jawed, G., Ganjoo, K. N.
2023; 16 (1): 886-892
- **Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)**
Lee, E., Rodon, J., Demeure, M., Deming, D., Federman, N., McKean, M., Spira, A., Kwiatkowski, D., Hussein, M., Gordon, E., Crockett, D., Ganjoo, K., Schulte, et al
ACADEMIC PRESS INC ELSEVIER SCIENCE.2023: S185
- **Response to treatment with nab-sirolimus among patients with primary uterine PEComa: A sub analysis from AMPECT**
Palma, N., Navarro, W., Ravi, V., Dickson, M., Ganjoo, K., Ding, L., Schmid, A., Wagner, A.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2023: S180-S181
- **MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients.** *European radiology*
Düx, D. M., Baal, J. D., Bitton, R., Chen, J., Brunsing, R. L., Sheth, V. R., Rosenberg, J., Kim, K., Ozhinsky, E., Avedian, R., Ganjoo, K., Bucknor, M., Dobrotwir, et al
2023
- **Management Strategies and Outcomes in Primary Liver Angiosarcoma.** *American journal of clinical oncology*
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., Ganjoo, K.
2023
- **Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.** *Cancer research communications*
Testa, S., Bui, N. Q., Ganjoo, K. N.
2023; 3 (7): 1212-1223
- **LBA11504 Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.** *JOURNAL OF CLINICAL ONCOLOGY*
Eulo, V., Toeniskoetter, J., Ruff, T., Luo, J., Kemp, L., Moreno Tellez, C., Weiss, M. C., Hirbe, A. C., Meyer, C., Elias, A. D., Diamond, M., Hartner, L. P., Bui, et al
2023; 41 (17_SUPPL): LBA11504
- **Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma**
Van Tine, B., Eulo, V., Toeniskoetter, J., Ruff, T., Luo, J., Kemp, L., Tellez, C., Weiss, M. C., Hirbe, A. C., Meyer, C., Elias, A. D., Diamond, M., Hartner, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma**
Van Tine, B., Ganjoo, K. N., Blay, J., Valverde, C., Araujo, D. M., Razak, A., Le Cesne, A., Schuetze, S., Wagner, M. J., Attia, S., Forcade, E., Druta, M., Pollack, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.**
D'Angelo, S. P., Ganjoo, K. N., Blay, J., Valverde, C., Araujo, D. M., Abdul Razak, A., Le Cesne, A., Schuetze, S., Wagner, M. J., Attia, S., Forcade, E., Druta, M., Pollack, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: e14531
- **Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).**

- Iyer, G., Deming, D. A., Demeure, M. J., Federman, N., McKean, M., Lee, E., Spira, A. I., Kwiatkowski, D. J., Hussein, M. A., Gordon, E., Crockett, D. G., Ganjoo, K. N., Schulte, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: TPS3168
- **The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma**
Van Tine, B., Ganjoo, K. N., Blay, J., Valverde, C., Araujo, D. M., Abdul Razak, A., Le Cesne, A., Schuetze, S., Wagner, M. J., Attia, S., Forcade, E., Druta, M., Pollack, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: 11563
 - **Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)**
Iyer, G., Deming, D. A., Demeure, M. J., Federman, N., McKean, M., Lee, E., Spira, A. I., Kwiatkowski, D. J., Hussein, M. A., Gordon, E., Crockett, D. G., Ganjoo, K. N., Schulte, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.**
D'Angelo, S. P., Ganjoo, K. N., Blay, J., Valverde, C., Araujo, D. M., Razak, A., Le Cesne, A., Schuetze, S., Wagner, M. J., Attia, S., Forcade, E., Druta, M., Pollack, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.** *International journal of molecular sciences*
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., Pan, M.
2023; 24 (11)
 - **A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.** *Cancers*
Bui, N., Dietz, H., Farag, S., Hirbe, A. C., Wagner, M. J., Van Tine, B. A., Ganjoo, K., Jones, R. L., Keedy, V. L., Davis, E. J.
2023; 15 (9)
 - **Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H. C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., Moding, et al
2023
 - **Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).**
Iyer, G., Demeure, M. J., Deming, D. A., Federman, N., McKean, M., Lee, E., Spira, A. I., Kwiatkowski, D. J., Hussein, M. A., Gordon, E., Crockett, D. G., Ganjoo, K. N., Schulte, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).**
Deming, D. A., Ahnert, J., Demeure, M. J., Federman, N., McKean, M., Lee, E., Spira, A. I., Kwiatkowski, D. J., Hussein, M. A., Gordon, E., Crockett, D. G., Ganjoo, K. N., Schulte, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: TPS818
 - **PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)**
Rodon, J., Demeure, M., Deming, D., Federman, N., Mckean, M., Lee, E., Spira, A., Kwiatkowski, D., Hussein, M., Gordon, E., Crockett, D., Ganjoo, K., Schulte, et al
BMJ PUBLISHING GROUP.2022: A231-A232
 - **Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy.** *Practical radiation oncology*
Baniel, C., Yoo, C. H., Jiang, A., von Eyben, R., Mohler, D. G., Ganjoo, K., Bui, N., Donaldson, S. S., Million, L., Rijn, M. v., Moon Oh, J., Hiniker, S. M.
2022
 - **Enrollment of pediatric and adolescent patients with MAGE-A4+advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel ("afami-cel" [formerly ADP-A2M4])**

- Lunt, C., D'Angelo, S. P., Razak, A., Wagner, M. J., Van Tine, B. A., Ganjoo, K., Blay, J., Araujo, D. M., Agulnik, M., Glod, J. W., Van Winkle, E., Elefant, E., Biswas, et al
AMER ASSOC CANCER RESEARCH.2022: 3-4
- **Enrollment of pediatric and adolescent patients with MAGE-A4+advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel ("afami-cel" [formerly ADP-A2M4])**
Lunt, C., D'Angelo, S. P., Razak, A., Wagner, M. J., Van Tine, B. A., Ganjoo, K., Blay, J., Araujo, D. M., Agulnik, M., Glod, J. W., Van Winkle, E., Elefant, E., Biswas, et al
AMER ASSOC CANCER RESEARCH.2022
 - **Interactions in CSF1-driven Tenosynovial Giant Cell Tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
van IJzendoorn, D. G., Matusiak, M., Charville, G. W., Spierenburg, G., Varma, S., Colburg, D. R., van de Sande, M. A., van Langevelde, K., Mohler, D. G., Ganjoo, K. N., Bui, N. Q., Avedian, R. S., Bovee, et al
2022
 - **Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.** *Clinical orthopaedics and related research*
Healey, J. H., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K., Martin-Broto, J., Wang, et al
2022
 - **A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.** *Cancer medicine*
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D., Loggers, E. T., Livingston, M. B., Wright, J., Chawla, S. P., Okuno, S. H., Reinke, D. K., Riedel, et al
2022
 - **Cutaneous Angiosarcoma of the Head and Neck-A Retrospective Analysis of 47 Patients.** *Cancers*
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., Ganjoo, K.
2022; 14 (15)
 - **First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass** *CUREUS JOURNAL OF MEDICAL SCIENCE*
Narayan, R. R., Charville, G. W., Delitto, D., Ganjoo, K. N.
2022; 14 (6)
 - **nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.**
Dickson, M., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B., Chugh, R., Cranmer, L. D., Gordon, E., Chen, J., Murphy, M., Schmid, A. N., Desai, N., Palma, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
 - **First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass.** *Cureus*
Narayan, R. R., Charville, G. W., Delitto, D., Ganjoo, K. N.
2022; 14 (6): e26356
 - **Local control outcomes using stereotactic body radiotherapy or surgical resection for metastatic sarcoma.** *International journal of radiation oncology, biology, physics*
Gutkin, P. M., von Eyben, R., Chin, A., Donaldson, S. S., Oh, J., Jiang, A., Ganjoo, K. N., Avedian, R. S., Bruzoni, M., Steffner, R. J., Moding, E. J., Hiniker, S. M.
2022
 - **Current management and recent progress in desmoid tumors.** *Cancer treatment and research communications*
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ghanouni, P., Ganjoo, K. N.
2022; 31: 100562
 - **Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Gounder, M. M., Razak, A. A., Somaiah, N., Chawla, S., Martin-Broto, J., Grignani, G., Schuetze, S. M., Vincenzi, B., Wagner, A. J., Chmielowski, B., Jones, R. L., Riedel, R. F., Stacchiotti, et al
2022: JCO2101829

- **Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.** *JAMA oncology*
Jones, R. L., Ravi, V., Brohl, A. S., Chawla, S., Ganjoo, K. N., Italiano, A., Attia, S., Burgess, M. A., Thornton, K., Cranmer, L. D., Cheang, M. C., Liu, L., Robertson, et al
2022
- **Post-operative Stereotactic Radiosurgery of Malignant Melanotic Schwannoma.** *Cureus*
Hall, J. C., Chang, S. D., Wilson, T. J., Ganjoo, K. N., Toland, A., Vogel, H., Pollom, E. L., Rahimy, E.
2022; 14 (3): e22849
- **Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.** *PLoS one*
Przybyl, J., Spans, L., Ganjoo, K., Bui, N., Mohler, D., Norton, J., Poultides, G., Debiec-Rychter, M., van de Rijn, M.
2022; 17 (1): e0262272
- **NCCN Guidelines Insights: Gastrointestinal Stromal Tumors, Version 2.2022.** *Journal of the National Comprehensive Cancer Network : JNCCN*
von Mehren, M., Kane, J. M., Riedel, R. F., Sicklick, J. K., Pollack, S. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, et al
2022; 20 (11): 1204-1214
- **Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., Holder, A., Homsy, J., Keedy, et al
2022; 20 (7): 815-833
- **Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.** *Cancers*
Testa, S., Bui, N. Q., Wang, D. S., Louie, J. D., Sze, D. Y., Ganjoo, K. N.
2022; 14 (2)
- **Genomic Predictors of Recurrence Patterns in Localized Soft Tissue Sarcoma Treated With Radiation Therapy.** *International journal of radiation oncology, biology, physics*
Devine, M., Chin, A. L., Million, L., Ganjoo, K. N., Bui, N. Q., Moding, E. J.
2021; 111 (3S): e316
- **Genomic Predictors of Recurrence Patterns in Localized Soft Tissue Sarcoma Treated With Radiation Therapy**
Devine, M., Chin, A. L., Million, L., Ganjoo, K. N., Bui, N. Q., Moding, E. J.
ELSEVIER SCIENCE INC.2021: E316
- **Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
O'Sullivan Coyne, G., Kummar, S., Hu, J., Ganjoo, K., Chow, W. A., Do, K. T., Zlott, J., Bruns, A., Rubinstein, L., Foster, J. C., Jawara, L., Meehan, R., Piekarz, et al
2021
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Safety and Feasibility of Cryoablation during Immunotherapy in Patients with Metastatic Soft Tissue Sarcoma.** *Journal of vascular and interventional radiology : JVIR*
Doshi, A., Zhou, M., Bui, N., Wang, D. S., Ganjoo, K., Hwang, G. L.
2021
- **Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.** *European journal of cancer (Oxford, England : 1990)*
George, S., Chi, P., Heinrich, M. C., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Razak, A. A., Gordon, M. S., Somaiah, N., Jennings, J., Meade, et al
2021; 155: 236-244

- **Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib**
Patel, A., George, S., Janku, F., Ganjoo, K., Young, R., Chi, P., Westwood, D., Stearns, S., Meade, J., Ruiz-Soto, R., Lacouture, M.
ELSEVIER.2021: S134-S135
- **Skin angiography assisted mastectomy in secondary breast angiosarcoma: Complete clinical response after neoadjuvant immunotherapy.** *The breast journal*
Ju, T., Foster, D., Titan, A., Najjar, S., Bean, G. R., Ganjoo, K., Wapnir, I.
2021
- **Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**
Van Tine, B., Hirbe, A. C., Luo, J., Oppelt, P., Weiss, M. C., Eulo, V., Toeniskoetter, J., Haarberg, S., Abaricia, S., Ruff, T., Bomalaski, J. S., Johnston, A., Kuo, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).**
D'Angelo, S. P., Noujaim, J., Thistlethwaite, F., Razak, A., Stacchiotti, S., Chow, W., Haanen, J. G., Chalmers, A., Robinson, S., Van Tine, B., Ganjoo, K. N., Johnson, M. L., Chiou, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations.**
Dickson, M., Ravi, V., Ganjoo, K. N., Iyer, G.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).**
Schuetze, S., Ballman, K. V., Ganjoo, K. N., Davis, E. J., Morgan, J. A., Tinoco, G., Burgess, M., Van Tine, B., Choy, E., Shepard, D., Kelly, C., Riedel, R. F., von Mehren, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial** *ACTA ORTHOPAEDICA*
van de Sande, M., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K., Martin-Broto, J., Wang, et al
2021
- **Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.** *British journal of haematology*
Choi, S., Zhou, M., Bahrani, E., Martin, B. A., Ganjoo, K. N., Zaba, L. C.
2021
- **Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.** *The Permanente journal*
Pan, M., Ganjoo, K., Karam, A.
2021; 25
- **Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma.** *JAMA network open*
Brewster, R., Purington, N., Henry, S., Wood, D., Ganjoo, K., Bui, N.
2021; 4 (3): e210845
- **Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression.** *Case reports in oncology*
Zhou, M., Bui, N., Lohman, M., van de Rjin, M., Hwang, G., Ganjoo, K.
2021; 14 (1): 459–65
- **Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course.** *American journal of clinical oncology*
Yurkiewicz, I. R., Zhou, M., Ganjoo, K. N., Charville, G. W., Bolleddu, S., Lohman, M., Bui, N.
2021
- **Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review.** *Surgical oncology*

- Zhou, M., Javadi, C., Charville, G. W., Bui, N. Q., Harris, E. J., Poultides, G. A., Norton, J. A., Visser, B., Lee, B., Dua, M. M., Ganjoo, K. N.
2021; 39: 101670
- **A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.** *Current oncology (Toronto, Ont.)*
Testa, S., Hu, B. D., Saadeh, N. L., Pribnow, A., Spunt, S. L., Charville, G. W., Bui, N. Q., Ganjoo, K. N.
2021; 28 (6): 5304-5317
 - **nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., Grigorian, B., Schmid, A. N., Hou, et al
2021: JCO2101728
 - **Fusion and rearrangement (RE) detection using DNA and RNA-based comprehensive genomic profiling (CGP) of sarcomas**
Ganjoo, K., Madison, R., Rosenzweig, M., Oxnard, G., Venstrom, J., Ward, A., Schrock, A. B.
ELSEVIER.2021: S1116-S1117
 - **Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Chawla, S. P., Van Tine, B. A., Pollack, S. M., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, et al
2021: JCO2003452
 - **Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I**
Janku, F., Chi, P., Heinrich, M., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Razak, A., Gordon, M., Somaiah, N., Jennings, J., Shi, et al
ELSEVIER.2020: S974–S975
 - **Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Janku, F., Abdul Razak, A. R., Chi, P., Heinrich, M. C., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Somaiah, N., Hu, S., Rosen, O., Su, et al
2020: JCO2000522
 - **A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib vs. Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.** *The oncologist*
Riedel, R. F., Ballman, K. V., Attia, S., Loggers, E. T., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J., Ward, J. H., Rushing, D., Okuno, S. H., Reed, D. R., Liebner, et al
2020
 - **Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.**
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B., Chugh, R., Cranmer, L. D., Gordon, E., Hornick, J. L., Kwiatkowski, D. J., Du, H., Grigorian, B., Schmid, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.** *Immunotherapy*
Zhou, M. n., Bui, N. n., Bolleddu, S. n., Lohman, M. n., Becker, H. C., Ganjoo, K. n.
2020
 - **Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.** *JAMA*
Tap, W. D., Wagner, A. J., Schöffski, P. n., Martin-Broto, J. n., Krarup-Hansen, A. n., Ganjoo, K. N., Yen, C. C., Abdul Razak, A. R., Spira, A. n., Kawai, A. n., Le Cesne, A. n., Van Tine, B. A., Naito, et al
2020; 323 (13): 1266–76
 - **Angiosarcoma of the Breast: Management and Outcomes.** *American journal of clinical oncology*
Gutkin, P. M., Ganjoo, K. N., Lohman, M. n., von Eyben, R. n., Charville, G. W., Nazerali, R. S., Dirbas, F. M., Horst, K. C.
2020

- **Sinonasal FUS-ERG-Rearranged Ewing's Sarcoma Mimicking Glomangiopericytoma.** *Case reports in oncology*
Zhou, M. n., Ko, Y. C., Charville, G. W., Ganjoo, K. N.
2020; 13 (3): 1393–96
- **Tenosynovial giant cell tumor of the suboccipital region - A rare, benign neoplasm in this location.** *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*
Singh, R. n., Stienen, M. N., Ganjoo, K. n., Kolahi, K. S., Cayrol, R. n., Charville, G. W., Born, D. E., Zygourakis, C. C.
2020
- **Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)**
Chi, P., Janku, F., Heinrich, M., Ganjoo, K., Gelderblom, H., Gordon, M., Jones, R., Razak, A., Trent, J., von Mehren, M., Hu, S., Su, Y., Ruiz-Soto, et al
AMER ASSOC CANCER RESEARCH.2019
- **Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas.** *JCO precision oncology*
Przybyl, J., Spans, L., Lum, D. A., Zhu, S., Vennam, S., Forgó, E., Varma, S., Ganjoo, K., Hastie, T., Bowen, R., Debiec-Rychter, M., van de Rijn, M.
2019; 3
- **Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)**
Jones, R. L., Ravi, V., Brohl, A. S., Chawla, S. P., Ganjoo, K., Italiano, A., Attia, S., Burgess, M., Thornton, K., Cranmer, L., Liu, L., Theuer, C., Maki, et al
OXFORD UNIV PRESS.2019: 683
- **Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs)**
Janku, F., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K., Trent, J., Jones, R. L., Gelderblom, H., Running, K., Wang, J., Ruiz-Soto, et al
AMER ASSOC CANCER RESEARCH.2019
- **ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) plus olaratumab versus dox plus PBO in patients (pts) with advanced soft tissue sarcomas (STS).**
Tap, W. D., Wagner, A. J., Papai, Z., Ganjoo, K. N., Yen, C., Schoffski, P., Razak, A., Martin Broto, J., Spira, A. I., Kawai, A., Krarup-Hansen, A., Le Cesne, A., Van Tine, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Uterine sarcomas.** *Current problems in cancer*
Ganjoo, K. N.
2019
- **Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma** *JOURNAL OF CLINICAL ONCOLOGY*
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, et al
2019; 37 (16): 1424-+
- **A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.**
Chawla, S. P., Van Tine, B., Pollack, S., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**
Van Tine, B., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B., Chawla, S. P., Ganjoo, K. N., Oppelt, P., Hirbe, A. C.
AMER SOC CLINICAL ONCOLOGY.2019
- **Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).**
Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Keedy, V., Davis, E. J.
AMER SOC CLINICAL ONCOLOGY.2019
- **ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.**

- Wagner, A. J., Ravi, V., Ganjoo, K. N., Van Tine, B., Riedel, R. F., Chugh, R., Cranmer, L. D., Gordon, E., Hornick, J. L., Kwiatkowski, D. J., Du, H., Grigorian, B., Schmid, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Responder analysis of patient-reported outcomes measurement information system (PROM'S) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.**
Tap, W. D., Speck, R. M., Ye, X., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K. N., Broto, J., Wang, Q., Shuster, D., Gelhorn, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, et al
2019: JCO1802374
 - **The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Kamat, N. V., Million, L., Yao, D., Donaldson, S. S., Mohler, D. G., van de Rijn, M., Avedian, R. S., Kapp, D. S., Ganjoo, K. N.
2019; 42 (2): 166–71
 - **Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.** *Lancet (London, England)*
Tap, W. D., Gelderblom, H. n., Palmerini, E. n., Desai, J. n., Bauer, S. n., Blay, J. Y., Alcindor, T. n., Ganjoo, K. n., Martin-Broto, J. n., Ryan, C. W., Thomas, D. M., Peterfy, C. n., Healey, et al
2019
 - **A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.** *Clinical sarcoma research*
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., Ganjoo, K. N.
2019; 9: 12
 - **The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University.** *American journal of clinical oncology*
Kamat, N. V., Million, L., Yao, D., Donaldson, S. S., Mohler, D. G., van de Rijn, M., Avedian, R. S., Kapp, D. S., Ganjoo, K. N.
2018
 - **The impact of postoperative therapy on primary cardiac sarcoma.** *The Journal of thoracic and cardiovascular surgery*
Wu, Y., Million, L., Moding, E. J., Scott, G., Berry, M., Ganjoo, K. N.
2018; 156 (6): 2194-2203
 - **Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens**
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Somaiah, N., Trent, J. C., Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, et al
OXFORD UNIV PRESS.2018
 - **Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.** *Annals of oncology : official journal of the European Society for Medical Oncology*
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Somaiah, N., Trent, J. C., Rodon Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, et al
2018; 29 Suppl 8: viii576–viii577
 - **Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma** *FUTURE ONCOLOGY*
Seetharam, M., Kolla, K. R., Ganjoo, K. N.
2018; 14 (23): 2323–33
 - **Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST)**
Janku, F., Heinrich, M., Razak, A., Gordon, M., Chi, P., Ganjoo, K., von Mehren, M., Somaiah, N., Lee, J., Kuida, K., Soto, R., Rosen, O., George, et al
AMER ASSOC CANCER RESEARCH.2018

- **Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib** *JAMA ONCOLOGY*
Schuetze, S. M., Bolejack, V., Thomas, D. G., von Mehren, M., Patel, S., Samuels, B., Choy, E., D'Amato, G., Staddon, A. P., Ganjoo, K. N., Chow, W. A., Rushing, D. A., Forscher, et al
2018; 4 (6): 814–20
- **Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.**
George, S., Heinrich, M. C., Razak, A., Chi, P., Gordon, M. S., Ganjoo, K. N., von Mehren, M., Somaiah, N., Trent, J. C., Su, Y., Ruiz-Soto, R., Rosen, O., Janku, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Decreased lymphocyte count at diagnosis as a marker for worse outcome in localized sarcoma.**
Bui, N., Henry, S., Ganjoo, K. N.
AMER SOC CLINICAL ONCOLOGY.2018
- **Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).**
Wagner, A. J., Riedel, R. F., Van Tine, B., Chugh, R., Ganjoo, K. N., Cranmer, L. D., Pollack, S., Sankhala, K., Gordon, E., Ravi, V., Hornick, J. L., Kwiatkowski, D. J., Grigorian, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.**
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J. A., Ward, J., Rushing, D. A., Okuno, S. H., Reed, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).**
Tap, W. D., Gelderblom, H., Stacchiotti, S., Palmerini, E., Ferrari, S., Desai, J., Bauer, S., Blay, J., Alcindor, T., Ganjoo, K. N., Broto, J., Ryan, C. W., Shuster, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **CDKN2A deletion as a prognostic marker: A clinico-genomic analysis of sarcoma patients.**
Nam Bui, Przybyl, J., Million, L., Van De Rijn, M., Ganjoo, K. N.
AMER SOC CLINICAL ONCOLOGY.2018
- **Soft Tissue Sarcoma, Version 2.2018** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Randall, R., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Keedy, V., Kim, E., Koon, et al
2018; 16 (5): 536–63
- **Circulating tumor DNA levels correlate with response to treatment in LMS patients**
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A., Diehn, M., van de Rijn, et al
AMER ASSOC CANCER RESEARCH.2018: 38–39
- **The Impact of Post-Operative Therapy on Primary Cardiac Sarcoma** *The Journal of Thoracic and Cardiovascular Surgery*
Wu, Y., Million, L., Moding, E. J., Scott, G., Berry, M., Ganjoo, K. N.
2018
- **Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Przybyl, J. n., Chabon, J. J., Spans, L. n., Ganjoo, K. n., Vennam, S. n., Newman, A. M., Forgo, E. n., Varma, S. n., Zhu, S. n., Debiec-Rychter, M. n., Alizadeh, A. A., Diehn, M. n., van de Rijn, et al
2018
- **Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT.** *Clinical nuclear medicine*
Yurkiewicz, I. R., Ganjoo, K. N., Iagaru, A. n.
2018

- **A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. *Rare tumors***
Bui, N. n., Kamat, N. n., Ravi, V. n., Chawla, S. n., Lohman, M. n., Ganjoo, K. N.
2018; 10: 2036361318771771
- **Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial *GYNECOLOGIC ONCOLOGY***
Hensley, M. L., Patel, S. R., von Mehren, M., Ganjoo, K., Jones, R. L., Staddon, A., Rushing, D., Milhem, M., Monk, B., Wang, G., McCarthy, S., Knoblauch, R. E., Parekh, et al
2017; 146 (3): 531–37
- **Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARCO21): an international, multicentre, open-label, randomised phase 3 trial *LANCET ONCOLOGY***
Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S., Reed, D., Chawla, S. P., Riedel, R. F., Krarup-Hansen, A., Toulmonde, M., Ray-Coquard, et al
2017; 18 (8): 1089–1103
- **Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma *BRITISH JOURNAL OF HAEMATOLOGY***
Martin, P., Chen, Z., Cheson, B. D., Robinson, K. S., Williams, M., Rajguru, S. A., Friedberg, J. W., van der Jagt, R. H., LaCasce, A. S., Joyce, R., Ganjoo, K. N., Bartlett, N. L., Lemieux, et al
2017; 178 (2): 250–56
- **A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARCO24 trial results**
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D. A., Loggers, E., Livingston, M. B., Wright, J. A., Chawla, S. P., Okuno, S. H., Reinke, D. K., Riedel, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas**
Chawla, S. P., Ganjoo, K. N., Schuetze, S., Papai, Z., Van Tine, B., Choy, E., Liebner, D. A., Agulnik, M., Chawla, S., Wieland, S., Levitt, D. J.
AMER SOC CLINICAL ONCOLOGY.2017
- **Improving care with portfolio of physician-led cancer quality measures at an academic center**
Porter, J., Smith, A., Winget, M., Rosenthal, E., Seshadri, S., Vetteth, Y., Kiamanesh, E. F., Badwe, A., Advani, R. H., Buyyounouski, M. K., Coutre, S., Dorigo, O., Ganjoo, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study *EUROPEAN RADIOLOGY***
Ghanouni, P., Dobrotwir, A., Bazzocchi, A., Bucknor, M., Bitton, R., Rosenberg, J., Telischak, K., Busacca, M., Ferrari, S., Albisinni, U., Walters, S., Gold, G., Ganjoo, et al
2017; 27 (2): 732-740
- **Phase 2 Study of Dasatinib in Patients With Alveolar Soft Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid Sarcoma, or Solitary Fibrous Tumor *CANCER***
Schuetze, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D'Amato, G., Leu, K. M., Loeb, et al
2017; 123 (1): 90-97
- **Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors. *Sarcoma***
Moding, E. J., Million, L., Avedian, R., Ghanouni, P., Kunder, C., Ganjoo, K. N.
2017; 2017: 2316839
- **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center***
Porter, J. B.
2017; 13 (8): e673-e682
- **Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. *Cancer***

- Schuetze, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D'Amato, G., Leu, K. M., Loeb, et al
2016
- **Soft Tissue Sarcoma, Version 2.2016 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Koon, H., Mayerson, et al
2016; 14 (6): 758-786
 - **Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study.** *European radiology*
Ghanouni, P., Dobrotwir, A., Bazzocchi, A., Bucknor, M., Bitton, R., Rosenberg, J., Telischak, K., Busacca, M., Ferrari, S., Albisinni, U., Walters, S., Gold, G., Ganjoo, et al
2016: -?
 - **SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.** *Cancer*
Schuetze, S. M., Wathen, J. K., Lucas, D. R., Choy, E., Samuels, B. L., Staddon, A. P., Ganjoo, K. N., von Mehren, M., Chow, W. A., Loeb, D. M., Tawbi, H. A., Rushing, D. A., Patel, et al
2016; 122 (6): 868-874
 - **Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.** *Journal of clinical oncology*
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., Van Tine, B. A., Spira, A., Dean, et al
2016; 34 (8): 786-793
 - **First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.** *JAMA oncology*
Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., Khamly, K., Ganjoo, K., Nagarkar, R., Wieland, S., Levitt, D. J.
2015; 1 (9): 1272-1280
 - **First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial** *JAMA ONCOLOGY*
Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., Khamly, K., Ganjoo, K., Nagarkar, R., Wieland, S., Levitt, D. J.
2015; 1 (9): 1272-1280
 - **Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study** *ANNALS OF SURGERY*
Poultides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A.
2015; 262 (4): 632-640
 - **Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study.** *Annals of surgery*
Poultides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A.
2015; 262 (4): 632-40
 - **Combined F-18-NaF and F-18-FDG PET/CT in the Evaluation of Sarcoma Patients** *CLINICAL NUCLEAR MEDICINE*
Jackson, T., Mosci, C., von Eyben, R., Mitra, E., Ganjoo, K., Biswal, S., Gambhir, S. S., Igaru, A.
2015; 40 (9): 720-724
 - **Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.** *journal of hand surgery*
Park, M. J., Ganjoo, K. N., Ladd, A. L.
2015; 40 (8): 1620-1624
 - **Clinically Relevant Molecular Subtypes in Leiomyosarcoma.** *Clinical cancer research*
Guo, X., Jo, V. Y., Mills, A. M., Zhu, S. X., Lee, C., Espinosa, I., Nucci, M. R., Varma, S., Forgó, E., Hastie, T., Anderson, S., Ganjoo, K., Beck, et al
2015; 21 (15): 3501-3511
 - **Leiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin?** *JOURNAL OF SURGICAL ONCOLOGY*
Worhunsky, D. J., Gupta, M., Gholami, S., Tran, T. B., Ganjoo, K. N., van de Rijn, M., Visser, B. C., Norton, J. A., Poultides, G. A.

2015; 111 (7): 808-812

- **Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc γ R1a Patients with Previously Treated Follicular Lymphoma.** *Leukemia & lymphoma*
Ganjoo, K. N., de Vos, S., Pohlman, B. L., Flinn, I. W., Forero-Torres, A., Enas, N. H., Cronier, D. M., Dang, N. H., Foon, K. A., Carpenter, S. P., Slapak, C. A., Link, B. K., Smith, et al
2015; 56 (1): 42-48
- **Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study** *ACTA ONCOLOGICA*
Martin-Broto, J., Cleeland, C. S., Glare, P. A., Engellau, J., Skubitza, K. M., Blum, R. H., Ganjoo, K. N., Staddon, A., Dominkus, M., Feng, A., Qian, Y., Braun, A., Jacobs, et al
2014; 53 (9): 1173-1179
- **Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.** *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803
- **Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).**
von Mehren, M., George, S., Heinrich, M. C., Schuetze, S., Belinsky, M. G., Janeway, K. A., Rink, L., Ganjoo, K. N., Yu, J., Yap, J. T., Wright, J., Van den Abbeele, A. D.
AMER SOC CLINICAL ONCOLOGY.2014
- **Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).** *Leukemia & lymphoma*
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.
2014; 55 (4): 768-772
- **Soft tissue sarcoma, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al
2014; 12 (4): 473-483
- **The Treatment Outcome for Adult Patients with Ewing's Sarcoma.** *Current oncology reports*
Ganjoo, K. N., Patel, S.
2013; 15 (4): 372-377
- **Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R., Heslin, M. J., Kane, J. M., Mayerson, J., McGarry, et al
2012; 10 (8): 951-960
- **Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., Lebensohn, A., Ford, J. M., Telli, M. L.
2012; 10 (8): 939-942
- **Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial** *LEUKEMIA & LYMPHOMA*
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., Habermann, T. M., Ganjoo, K.
2012; 53 (4): 718-720
- **Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer** *CANCER INVESTIGATION*
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., Colevas, A. D., San Pedro-Salcedo, M., Kuo, C. J., Wakelee, H. A.
2012; 30 (3): 231-235
- **Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma R1a-Genotyped Patients with Previously Treated Follicular Lymphoma** *CLINICAL CANCER RESEARCH*

- Forero-Torres, A., de Vos, S., Pohlman, B. L., Pashkevich, M., Cronier, D. M., Dang, N. H., Carpenter, S. P., Allan, B. W., Nelson, J. G., Slapak, C. A., Smith, M. R., Link, B. K., Wooldridge, et al
2012; 18 (5): 1395-1403
- **The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Ganjoo, K. N., Witten, D., Patel, M., Espinosa, I., La, T., Tibshirani, R., van de Rijn, M., Jacobs, C., West, R. B.
2011; 34 (1): 82-86
 - **A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., Zhao, G., Padda, S., Zhou, L., San Pedro-Salcedo, M., Colevas, A. D., Wakelee, H. A.
2010; 5 (11): 1821-1825
 - **TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin** *22nd European Organization for Research and Treatment of Cancer (EORTC)-National-Cancer-Institute(NCI)-American-Association-for-Cancer-Research(AACR) Symposium on Molecular Targets and Cancer Therapeutics*
Hart, C. P., Borad, M., Chawla, S. P., Infante, J. R., Ganjoo, K. N., Langmuir, V. K., KROLL, S., Curd, J. G.
PERGAMON-ELSEVIER SCIENCE LTD.2010: 124-24
 - **I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma** *MOLECULAR IMAGING AND BIOLOGY*
Iagaru, A., Mitra, E. S., Ganjoo, K., Knox, S. J., Goris, M. L.
2010; 12 (2): 198-203
 - **Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study** *CANCER*
Kahl, B. S., Bartlett, N. L., Leonard, J. P., Chen, L., Ganjoo, K., Williams, M. E., Czuczman, M. S., Robinson, K. S., Joyce, R., Van der Jagt, R. H., Cheson, B. D.
2010; 116 (1): 106-114
 - **Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor.** *Case reports in oncology*
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., Ganjoo, K.
2009; 2 (3): 242-250
 - **Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.**
Advani, R. H., Hong, F., Ganjoo, K. N., Manola, J. B., Swinnen, L. J., Habermann, T. M., Horning, S. J.
AMER SOC HEMATOLOGY.2009: 667
 - **A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer**
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., Zhao, G., Padda, S., San Pedro-Salcedo, M., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2009: S674-S674
 - **Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors**
Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., Ganjoo, K., Le, Q., Maxim, P., Quon, A., Graves, E. E., Loo, B. W.
LIPPINCOTT WILLIAMS & WILKINS.2009: S939-S939
 - **Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma** *AMERICAN JOURNAL OF PATHOLOGY*
Espinosa, I., Beck, A. H., Lee, C., Zhu, S., Montgomery, K. D., Marinelli, R. J., Ganjoo, K. N., Nielsen, T. O., Gilks, C. B., West, R. B., van de Rijn, M.
2009; 174 (6): 2347-2356
 - **Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy** *LEUKEMIA & LYMPHOMA*
Ganjoo, K. N., Raman, R., Sobel, R. A., Pinto, H. A.
2009; 50 (4): 673-675
 - **Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor** *CASE REPORTS IN ONCOLOGY*
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., Ganjoo, K.
2009; 2 (3): 242-50

- **Breast angiosarcomas: Case series and expression of vascular endothelial growth factor** *Case Reports in Oncology*
Rondeep Brar, Robert West, Daniela Witten, Bhargav Raman, Charlotte Jacobs, Kristen Ganjoo
2009; 2: 242-50
- **Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity Fc gamma RIIa patients with previously-treated follicular lymphoma**
Forero, A., de Vos, S., Pohlman, B., Enas, N., Ganjoo, K. N., Cronier, D., Dang, N. H., Carpenter, S. P., Smith, M. R., Link, B. K., Wooldridge, J. E.
AMER ASSOC CANCER RESEARCH.2008
- **Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymph**
Levy, R., Robertson, M. J., Ganjoo, K., Leonard, J., Vose, J., Denney, D.
AMER ASSOC CANCER RESEARCH.2008
- **The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients** *JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY*
Ganjoo, K. N., Moore, A. M., Orazi, A., Sen, J. A., Johnson, C. S., An, C. S.
2008; 134 (3): 381-387
- **Review of erlotinib in the treatment of advanced non-small cell lung cancer** *Biologics; Targets & Therapy*
Kristen N Ganjoo, Heather Wakelee
2008
- **Review of erlotinib in the treatment of advanced non-small cell lung cancer.** *Biologics : targets & therapy*
Ganjoo, K. N., Wakelee, H.
2007; 1 (4): 335-346
- **Comparison of I-131-Tositumomab (Bexxar (R)) and Y-90-Ibritumomab (Zevalin (R)) therapy of refractory/relapsed non-Hodgkin lymphoma**
Iagaru, A., Zhu, H., Mari, C., Knox, S. J., Ganjoo, K., Goris, M. L.
SPRINGER.2007: S168
- **Non-Hodgkin lymphoma of the breast** *CANCER*
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., Horning, S.
2007; 110 (1): 25-30
- **Antiangiogenesis: A new approach to the treatment of lymphoma** *LEUKEMIA & LYMPHOMA*
Ganjoo, K.
2007; 48 (3): 454-455
- **Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis** *LEUKEMIA & LYMPHOMA*
Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A., Weisenbach, J., Li, S., Weller, E. A., Orazi, A., Horning, S. J.
2006; 47 (6): 998-1005
- **Phase II clinical studies of denileukin diftix diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia** *CANCER*
Frankel, A. E., Surendranathan, A., Black, J. H., White, A., Ganjoo, K., Cripe, L. D.
2006; 106 (10): 2158-2164
- **A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A Hoosier oncology group study** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Ganjoo, K. N., Robertson, M. J., Fisher, W., Jung, S. H., McClean, J., Huh, S. Y., Bufill, J., Williams, S., Cripe, L. D.
2005; 28 (2): 169-172
- **Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma** *JOURNAL OF CLINICAL ONCOLOGY*
Shafqat, A., Yum, M. N., Abanour, R., Ganjoo, K. N.
2003; 21 (17): 3368-3369
- **Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study** *ONCOLOGY*
Schneider, B. P., Ganjoo, K. N., Seitz, D. E., Picus, J., Fata, F., Stoner, C., Calley, C., Loehrer, P. J.

2003; 65 (3): 218-223

- **A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study** *ONCOLOGY*
Ganjoo, K. N., GORDON, M. S., Sandler, A. B., Warner, R. E., Fife, K., Poirier, S., Seshadri, R., Loehrer, P. J.
2002; 62 (4): 299-304
- **Germ cell tumor associated primitive neuroectodermal tumors** *JOURNAL OF UROLOGY*
Ganjoo, K. N., Foster, R. S., Michael, H., Donohue, J. P., Einhorn, L. H.
2001; 165 (5): 1514-1516
- **Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors** *35th Annual Meeting of the American-Society-of-Clinical-Oncology*
Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K., Einhorn, L. H.
JOHN WILEY & SONS INC.2000: 1051–56
- **Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma** *35th Annual Meeting of the American-Society-of-Clinical-Oncology*
Ganjoo, K. N., Chan, R. J., Sharma, M., Einhorn, L. H.
AMER SOC CLINICAL ONCOLOGY.1999: 3457–60
- **Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery** *79th Annual Meeting of the American-Association-for-Thoracic-Surgery*
Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. S., Einhorn, L. H., Brown, J. W.
MOSBY-ELSEVIER.1999: 692–700
- **Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella** *JOURNAL OF CLINICAL ONCOLOGY*
Ganjoo, K. N., Loyal, J. A., Cramer, H. M., Loehrer, P. J.
1999; 17 (9): 2995-2997
- **Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma.** *JSLs : Journal of the Society of Laparoendoscopic Surgeons*
Nezhat, C. n., Vu, M. n., Vang, N. n., Ganjoo, K. n., Karam, A. n., Folkins, A. n., Nezhat, A. n., Nezhat, F. n.
; 23 (4)